EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

Thomas Powles, Ariel G Kann iD, Daniel Castellano, Marine Gross-Goupil, Hiroyuki Nishiyama, Sergio Bracarda, Jørgen Bjerggaard Jensen, Lydia Makaroff, Shusuan Jiang, Ja Hyeon Ku, Se Hoon Park, Oscar Reig Torras und 20 weitere

New England Journal of Medicine · 18.12.2025 · 393 (24) · 2395-2408

DOI: 10.1056/nejmoa2511885 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 18.12.2025. Verfasst von Thomas Powles und 31 weiteren Autor:innen. Beteiligte Einrichtung: Barts Cancer Institute, National Institute for Health Research Biomedical Research Centre, Queen Mary University of London, London. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Circulating Tumor DNA, Cystectomy, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 208-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCirculating Tumor DNACystectomyNeoplasm Recurrence, LocalUrinary Bladder NeoplasmsImmune Checkpoint InhibitorsAgedAged, 80 and overFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantDisease-Free SurvivalDouble-Blind MethodNeoplasm InvasivenessNeoplasm, ResidualPatient SelectionInfusions, IntravenousAdult

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabCirculating Tumor DNAImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Barts Cancer Institute, National Institute for Health Research Biomedical Research Centre, Queen Mary University of London, London.
  • Hospital Alemão Oswaldo Cruz, São Paulo.
  • Hospital Universitario 12 de Octubre, Madrid.
  • University Hospital of Bordeaux, Bordeaux, France.
  • University of Tsukuba, Tsukuba, Japan.
  • Azienda Ospedaliera Santa Maria, Terni, Italy.

ORCID-Profile: Ariel G Kann, Emilio Francesco Giunta

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Powles, T., Kann, A. G., Castellano, D., Gross-Goupil, M., Nishiyama, H., Bracarda, S., Bjerggaard Jensen, J., Makaroff, L., Jiang, S., Ku, J. H., Park, S. H., Reig Torras, O., Ye, D., Maruzzo, M., Necchi, A., Morales-Barrera, R., Giunta, E. F., Lee, J. L., Tortora, G., …, & IMvigor011 Investigators (2025). ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. New England Journal of Medicine, 393(24), 2395-2408. https://doi.org/10.1056/nejmoa2511885

Vancouver

Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, et al. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. New England Journal of Medicine. 2025;393(24):2395-2408. doi:10.1056/nejmoa2511885

BibTeX
@article{Powles2025,
  author = {Powles, Thomas and Kann, Ariel G and Castellano, Daniel and Gross-Goupil, Marine and Nishiyama, Hiroyuki and Bracarda, Sergio and Bjerggaard Jensen, Jørgen and Makaroff, Lydia and Jiang, Shusuan and Ku, Ja Hyeon and Park, Se Hoon and Reig Torras, Oscar and Ye, Dingwei and Maruzzo, Marco and Necchi, Andrea and Morales-Barrera, Rafael and Giunta, Emilio Francesco and Lee, Jae Lyun and Tortora, Giampaolo and Ürün, Yüksel and Dolowy, Lukasz and Erdem, Dilek and Pinto, Alvaro and Grando, Fabricio and Zou, Wei and Assaf, Zoe June and Vuky, Jacqueline and Degaonkar, Viraj and Steinberg, Elizabeth E and Bellmunt, Joaquim and Gschwend, Jürgen E and IMvigor011 Investigators, IMvigor011 Investigators},
  title = {ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {24},
  pages = {2395--2408},
  doi = {10.1056/nejmoa2511885}
}
Kostenlos starten →